Disclosed herein are systems and methods for contributing to the local treatment of pain. More specifically, the disclosed systems and methods contribute to the local treatment of pain by inhibiting the NFκB family of transcription factors.

The present invention relates to a p75NTR neurotrophin binding protein (NBP)-Fc fusion protein comprising a p75NTR(NBP) portion and an immunoglobulin portion. In certain embodiments, the p75NTR(NBP)-Fc fusion protein is for use in the treatment of pain and/or a symptom of pain.

The present disclosure provides methods for the treatment of a mammal having a neurological condition, disease, or injury. The methods involve increasing the number of functional GABAergic interneurons at or near the site of the neurological disease, injury, or condition

The present invention relates to a method for screening a pain-inhibiting substance, said method comprising the steps of: (a) inserting a microdialysis probe into the L1 site of a spinal cord dorsal horn of a neuropathic pain animal model; (b) collecting a first test sample from the L1 site by microdialysis; (c) administering a pain-inhibiting candidate substance into the body of the animal model; (d) after having administered the pain inhibiting candidate substance, then collecting a second test sample from the L1 site by microdialysis; (e) measuring the concentrations of a pain indicator substance in the first test sample and second test sample respectively; and (f) comparing the concentrations of the pain indicator substance in the first test sample and second test sample.

Disclosed are methods for treating pain and tracking response to treatment. Also disclosed are methods for determining pain, including predicting future medical care facility visits for pain.

The present disclosure relates to a method for measuring the intensity of pain and, more particularly, provides a method capable of measuring the intensity of pain by providing a pain template.

Provided are an expression inhibitor of an inflammation promoting factor based on the discovery of a new factor influencing the expression amount/level of an inflammation promoting factor, and a development tool therefor. Provided are also a diagnostic agent and a diagnosis method for immune diseases, inflammatory diseases, painful conditions and similar. More specifically provided are: an expression inhibitor of an inflammation promoting factor containing at least one kind of inhibitor selected from the group consisting of RBMS2 expression inhibitor and RBMS2 function inhibitor; a screening method using as an indicator the expression or the function of RBMS2; an expression cassette useful for said method; as well as a diagnostic agent containing a product detection agent for RBMS2 gene expression and disease detection method using as an indicator RBMS2 gene expression amount/level.

The present disclosure relates to methods, compositions and products for treating pain, and/or pain related symptoms, associated with dysmenorrhea in a subject. In certain embodiments, the present disclosure provides a method of treating pain, and/or pain related symptoms, associated with dysmenorrhea in a subject, the method comprising intrauterine and/or vaginal administration to the subject of an effective amount of an agent that reduces activation of the innate immune system and thereby treating the pain and/or the pain related symptoms in the subject. Other embodiments are also disclosed.

The present disclosure teaches systems and methods of diagnosing and treating the distinct biologic components that contribute to chronic pain symptoms experienced by patients. A biologic sample is obtained from a patient. Levels of two or more biomarkers (e.g., methylmalonic acid, homocysteine, xanthurenic acid, 3-hydroxypropyl mercapturic acid (3-HPMA), pyroglutamate, hydroxymethylglutarate (HMG), quinolinic acid, kynurenine acid, 5-hydroxyindoleacetate (5-HIAA), vanilmandelate (VMA), and ethylmalonic acid) in the biologic sample are experimentally determined. Based on the existence of abnormal results in one or more biomarkers the patient is diagnosed as having the nerve health, oxidative stress, chronic inflammation pain, and/or neurotransmitter pain components to their chronic pain. Based on the resulting diagnoses administration of certain support compounds is directed. The patient may retest after a sufficient period of time to observe any longitudinal differences in the test results and adjust treatment accordingly. Further, the biomarker data gathered from pain-neutral and chronic pain patients (particularly those using opioid therapies) will be used to characterize biochemistries going forward.

The present disclosure relates to delta-2-tubulin and its use as a biomarker for determining if a subject is at risk of developing peripheral neuropathy or if a subject has developed peripheral neuropathy. The present disclosure further relates to methods for the treatment of peripheral neuropathy in a subject and assays for identifying compounds that can be used to treat and/or prevent peripheral neuropathy.